Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Expert Highlights Avelumab Trial and Future of Immunotherapy in Head and Neck Cancer

August 8th 2017

Nancy Y. Lee, MD, discusses the ongoing JAVELIN HEAD AND NECK 100 trial and the overall impact of immunotherapy for patients with head and neck cancer.

Dr. Burtness on Challenges Facing Immunotherapy in Head and Neck

August 7th 2017

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses challenges regarding immunotherapy for patients with head and neck cancer.

Dr. Bauml Discusses Immunotherapy Agents in Head and Neck Cancer

August 3rd 2017

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy agents in head and neck cancer.

Dr. Weiss on the Role of Immunotherapy in Head and Neck Cancer

August 3rd 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses the role of immunotherapy in head and neck cancer.

Erlotinib Linked to Improved Survival in HNSCC

July 30th 2017

Results showed that adding erlotinib to cisplatin and docetaxel was superior to chemotherapy alone for both overall survival and progression-free survival in head and neck squamous cell carcinoma.

Dr. Cohen on Immunotherapy in Head and Neck Squamous Cell Carcinoma

July 27th 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy in head and neck squamous cell carcinoma.

Dr. Bauml on CAR T-Cell Therapy in Head and Neck Cancer

July 27th 2017

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses CAR T-cell therapy in head and neck cancer.

Dr. Burtness on Immunotherapy Resistance in Head and Neck Cancer

July 27th 2017

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses immunotherapy resistance in head and neck cancer.

FDA Accepts sBLAs for 4-week Nivolumab Dosing Schedule

July 26th 2017

The FDA has accepted supplemental Biologics License Applications seeking to add a second dosing schedule for nivolumab (Opdivo) across all of the PD-1 inhibitor’s monotherapy indications.

Dr. Bauml on Next Steps for Immunotherapy in Head and Neck Cancer

July 25th 2017

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the next steps for immunotherapy in head and neck cancer.

Dr. Weiss on Immunotherapy Combinations in Head and Neck Cancer

July 25th 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses immunotherapy combinations in head and neck cancer.

Dr. Cohen Discusses NK-Directed Therapy in Head and Neck Cancer

July 25th 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses natural killer-directed therapy in head and neck cancer.

Pembrolizumab Falls Short in Phase III Head and Neck Cancer Trial

July 25th 2017

Pembrolizumab (Keytruda) did not meet the primary endpoint of overall survival in the phase III KEYNOTE-040 trial in patients with previously-treated recurrent or metastatic head and neck squamous cell carcinoma.

Expert Discusses Key Immunotherapy Trials and Next Steps in Head and Neck Cancer

July 21st 2017

Joshua Bauml, MD, discusses the current role of immunotherapy in this disease, potential next steps, and unmet needs in HPV-associated head and neck cancer.

Dr. Burtness on Combinations of Immunotherapy in Head and Neck Cancer

July 21st 2017

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses immunotherapy combinations for patients with head and neck cancer.

Dr. Cohen on CAR T-Cell Therapy for Head and Neck Cancer

July 20th 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses CAR T-cell therapy for patients with head and neck cancer.

Dr. Burtness on Immunotherapy and Radioresistance in Head and Neck Cancer

July 19th 2017

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses immunotherapy in patients with head and neck cancer who have radioresistance.

Dr. Weiss Discusses Current Clinical Trials in Head and Neck Cancer

July 19th 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses current clinical trials in head and neck cancer.

Expert Discusses Evolving Treatment Options in Head and Neck Cancer

July 19th 2017

Jared Weiss, MD, discusses the evolving role of immunotherapy and other promising developments in head and neck cancer.

Dr. Bauml Discusses Immunotherapy in Head and Neck Cancer

July 19th 2017

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy in head and neck cancer.